Phibro Animal Health price to free cash flow PAHC

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026: 160×
10-year median: 32.6×
Against its 10-year history: 100th; percentile: 0 is its lowest day, 100 its highest
10-year range: 12.7× to 160×
Peer median: 7.8×

Phibro Animal Health's price to free cash flow is 160× as of Oct 23, 2026.

That is above its ten-year median of 32.6×, higher than on 100% of days in the last ten years.

Over that time it ranged from 12.7× in Feb 2024 to 160× in Oct 2026.

The median for 10 large drugmakers of a similar size is 7.8×.

Price to free cash flow over time

median 32.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	160×	41.1×	160×
2025	45.1×	18.6×	68.1×
2024	21.0×	12.7×	115×
2023	114×	95.1×	114×
2022	52.4×	35.3×	62.4×
2021	39.2×	27.2×	72.0×
2020	25.5×	21.4×	43.5×
2019	31.1×	24.9×	31.1×
2018	27.3×	20.8×	37.2×
2017	21.8×	15.0×	42.8×
2016	42.9×	39.1×	60.7×
2015	47.6×	25.1×	142×

Against its peers

Companies in Drug Manufacturers - General nearest Phibro Animal Health's size, closest first, today.

Company	Price to free cash flow
PAHCPhibro Animal Health	160×
ANIPANI Pharmaceuticals	9.6×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	8.1×
OMEROmeros	n/m
HRMYHarmony Biosciences	n/m
PBHPrestige Consumer Healthcare	9.6×
AMPHAmphastar Pharmaceuticals	7.0×
NRIXNurix Therapeutics	7.5×
ABUSArbutus Biopharma	n/m
COLLCollegium Pharmaceutical	2.3×
Peer median	7.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Phibro Animal Health

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.